What if
 we found cancer early enough to make a difference

Finding cancer early can improve survival

The earlier that cancer is diagnosed, the greater the chance of successful treatment and survival.1 Often, symptoms of cancer may not appear until later stages when treatment options may be more aggressive and less effective, and the chances of survival are lower.2

Learn More

Introducing the Galleri™ test

The Galleri multi-cancer early detection test detects more than 50 types of cancer through a routine blood draw with a low false-positive rate of 0.5%.3

When a cancer signal is detected, the Galleri test predicts the origin of the cancer signal with high accuracy to help guide the next steps to diagnosis. Using the Galleri test alongside existing screening tools is expected to improve early cancer detection for patients at an elevated risk of cancer, such as those aged 50 or older.

Discover the Galleri Test

Performance supported by large clinical studies

The Galleri test’s performance is supported by rigorous clinical studies with more than 20,000 participants representing diverse populations.3 – 5

20,000+

participants

See how the Galleri test performed in these large clinical studies. 

See the Data

We’re here to help

If you have questions or would like to know more,
contact us or see our FAQs.

Get Support

Sign up for more information about the Galleri test

  1. Surveillance, Epidemiology, and End Results (SEER) Program (www​.seer​.can​cer​.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Submission. Includes persons aged 50 – 79 diagnosed 2006 – 2015 ​“Early/​Localized” includes invasive localized tumors that have not spread beyond organ of origin, ​“Late/​Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body. Noone AM, Howlader N, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975 – 2015, National Cancer Institute, Bethesda, MD, http://​seer​.can​cer​.gov/​c​s​r​/​1​9​7​5​_​2015/, based on November 2017 SEER data submission, posted to the SEER website April 2018.

  2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7 – 33.

  3. Klein E, et al. Clinical validation of a targeted methylation·based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.

  4. The Circulating Cell-Free Genome Atlas (CCGA) Study was a prospective, multi-center, case-control, observational study with longitudinal follow-up (overall population N=15,254).
  5. The PATHFINDER study is a prospective, multi-center study to evaluate the implementation of the Galleri test into clinical practice. A total of 6,662 participants without clinical suspicion of cancer have been enrolled with results returned to a study investigator. The study included men and women 50 – 79 years of age with and without a history of cancer.
CHAT